Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-20.59	-7.21	-13.56
Depreciation & Amortization	0.02	0.1	0.11
Loss (Gain) From Sale of Investments	0.12	1.22	2.32
Stock-Based Compensation	0.44	0.31	0.41
Provision & Write-off of Bad Debts	0.12	0.76	0.49
Other Operating Activities	0.24	-0.92	1
Change in Accounts Payable	0.8	0.78	0.03
Change in Other Net Operating Assets	0.78	-0.86	-1.34
Operating Cash Flow	-18.09	-5.82	-10.54
Capital Expenditures	-0.11	-	-
Investment in Securities	-11.89	-	-
Other Investing Activities	-	-	-1
Investing Cash Flow	-12	-	-1
Issuance of Common Stock	0.33	-	0.23
Other Financing Activities	-3.34	-	-
Financing Cash Flow	81.99	-	0.23
Net Cash Flow	51.91	-5.82	-11.32
Free Cash Flow	-18.2	-5.82	-10.54
Free Cash Flow Per Share	-4.55	-1.47	-2.71
Levered Free Cash Flow	-11.11	-3.44	-
Unlevered Free Cash Flow	-11.11	-3.44	-
Change in Net Working Capital	-3.22	-0.78	-

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q